Document is current

Article History

Received: 4 March 2020

Accepted: 24 August 2020

First Online: 1 September 2020

Ethics approval and consent to participate

: CFAS II was approved by the Cambridgeshire 4 Research Ethics Committee (07/MRE05/48), National Health Service (NHS) Health Research Authority, and local research ethics committees: Newcastle Primary Care Trust (PCT) Research and Development Department (2007EC001), Nottingham Research Ethics Committee 1 (07/H0403/105) and Cambridgeshire NHS PCT (L00808; please see: ). The 10/66 study was approved by the King’s College London research ethics committee and in all local countries: (a) Medical Ethics Committee of Peking University the Sixth Hospital (Institute of Mental Health, China); (b) the Memory, Depression Institute and Risk Diseases (IMEDER) Ethics Committee (Peru); (c) Finlay Albarran Medical Faculty of Havana Medical University Ethical Committee (Cuba); (d) Hospital Universitario de Caracas Ethics Committee (Venezuela); (e) Ethics Committee of Nnamdi Azikiwe University Teaching Hospital (Nigeria); (f) Consejo Nacional de Bioética y Salud (CONABIOS, Dominican Republic); (g) Christian Medical College (Vellore) Research Ethics Committee (India); (h) Instituto Nacional de Neurología y Neurocirugía Ethics Committee (Mexico); (i) Nnamdi Azikiwe University Teaching Hospital Nnewi Anambra State Ethics Committee (Nigeria). All procedures comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Written informed consents were obtained from all participants.

: Not applicable.

: None.